Regulatory Inspection in case of suspected fraud
Generally, scope and type of monitoring depends on a study risk profile and complexity, but interim monitoring visits (IMVs) usually occur with 4 to 8 weeks intervals (with the first IM to be performed at each study site soon after the inclusion of the first subject in order to avoid possible systematic mistakes).
It would be a very unlike situation when a CRA responsible for the investigational site has no concerns about the unusual recruitment rate (whether too low or high).
The CRA/project management should pay attention to the facts that:
- Too many subjects have been enrolled since the first IMV (for relatively rare pathologies). Even in-house the CRA should review copies of screening logs, contact the sites for follow-up, etc. (Cooley, S., 2008).
- Absence of screen failures alone does not necessarily mean fraud (rather careful pre-screening activities and experience of the site staff), but in conjunction with the high recruitment rate it is suspicious.
- No documented AEs or SAEs is also a very suspicious, especially if a particular AE is foreseen in the IB and the protocol. It is possible that there have been no SAEs at the site but taking into account the number of the enrolled patients, some of them should be on investigational drug and experience the expected AEs.
- Fraud with subjects’ informed consents (especially considering the number of consents in question) is a very serious suspicion. The CRA should describe it in the monitoring report and discuss with the Lead CRA (Project Team) his/her concerns. Depending on a CRO/Sponsor’s SOPs a decision to perform additional IMV or internal QA audit may be made.
The following must be clarified, and the next steps would be then:
- Average enrollment/screen failure/AE and SAE rates at the other study sites.
- Performance of this site in previous studies (if known).
- Whether or not study management team deems the site’s performance suspicious.
a) Prompt discussion of the concerns and the upcoming FDA inspection with the LCRA/Team Lead.
b) Scheduling the IM / QA audit depending on management/Sponsor’s decision.
c) Notifying the regulatory authorities about the suspected/ confirmed problems (according to MHRA regulations [n.d.] is obligatory within 7 days from the moment when Sponsor was notified, whereas FDA may conduct inspection upon receipt of a complaint about particular site’s performance or as a response to Sponsor’s concerns, [FDA, 2010]).
CONSEQUENCES (Khosla, R. et al., 2000; MHRA, n.d.):
– Site’s exclusion from the study.
– Inspection of site’s performance in all other studies ever conducted by the site.
– Exclusion of the data generated by the site from the final analysis.
– A temporary of forever debarment of the PI/site from participation in clinical trials.
– Legal proceedings.
– Study statistical power may be significantly affected, and study rescue will require additional time and money expenditures.
- Cooley, S. (2008) Monitoring for Quality: Innovative and Traditional Resources in a Risk-based Monitoring Program.
- FDA (2010) Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors. FDA Inspections of Clinical Investigators.
- Khosla, R., Verma, D.D., Kapur, A., Khosla, S. (2000) ‘Efficient Source Data Verification’, Indian Journal of Pharmacology, 32, pp.180-186.
- MHRA ( n.d.) New guidance on reporting breaches of Good Clinical Practice (GCP) or the trial protocol.
Upcoming Clinical Trials
NCT04593316Not yet recruitingStudy of Risk Factors for the Occurrence and Severity of Exertional Heatstroke in the Military EnvironmentConditions: Heat Stroke
NCT04593329Not yet recruitingConditions: Acute Pain
NCT04593368Not yet recruitingFecal Microbiome Transplantation (FMT) in Pediatric Patients Colonized With Antibiotic-resistant Pathogens Before Hematopoietic Stem Cell Transplantation (HSCT)Conditions: Antibiotic Resistant Strain
NCT04593381Not yet recruitingConditions: Ovarian Cancer; Oligometastatic Disease; Recurrent Ovary Cancer; Persistent
NCT04593394Not yet recruitingConditions: Asthma Chronic; Exercise-Induced Vocal Cord Dysfunction
NCT04593407Not yet recruitingEndoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions.Conditions: Neoplasms, Colorectal
NCT04593420Not yet recruitingTreatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.Conditions: Prostate Cancer
NCT04593433Not yet recruitingConditions: Social Isolation; Quality of Life; Well Aging; Frailty
NCT04593446RecruitingDifference of Surgical Site Infection Between Using Sodium Picosulfate Solution(PicosolutionⓇ) and Oral Sulfate Tablet(ORA·FANGⓇ) in Colorectal Cancer SurgeryConditions: Colorectal Cancer
NCT04593498Not yet recruitingConditions: Atrial Fibrillation; Atrial Flutter; Supraventricular Beat, Premature; Premature Supraventricular Beats; Premature Atrial Complex; Extrasystole, Atrial
Recent CRA jobs
Associate Director, Medical Communications (Pharmacovigilance)
Associate QA Auditor - ICD
Manager, Clinical Start Up- UK
Assoc QA Auditor/ QA Auditor I
Programmer Analyst II- Data Analytics
Senior Scientist - HPLC - GMP
Pharmaceutical Services Specialist
Principal Statistical Programmer (UK-Sheffield or Home-based UK)
Study Start Up Critical Path Manager/ Study Start-Up Lead
Laboratory Technician (Entry Level)